{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T07:00:41Z","timestamp":1773730841293,"version":"3.50.1"},"reference-count":50,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,12,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Considerable progress has been made in the treatment of multiple myeloma in the past decade with median survival for the disease improving significantly. This has come through a combination of better understanding of the disease biology and coordinated research into new treatment approaches including better supportive care. However, patients eventually become refractory to available treatments and succumb to the disease, highlighting the need to develop new treatment approaches. The genetic heterogeneity in the disease and clonal evolution under treatment pressure underlie the development of resistance, underscoring the need to develop more effective therapies that can eradicate the disease at initial treatment as well as the need for new classes of drugs with varying mechanisms of action. To this end, there has been intense focus on exploring novel approaches to therapy including small-molecule inhibitors targeting specific abnormalities, immune therapies including monoclonal antibodies and adaptive T-cell therapy, as well as epigenetic approaches. Although many of these drugs are in the early stages of clinical development, the early data appear to be very promising. Many of these drugs can be safely and effectively combined with the current treatment classes such as proteasome inhibitors and immunomodulatory drugs, further enhancing the treatment options for myeloma.<\/jats:p>","DOI":"10.1182\/asheducation-2017.1.518","type":"journal-article","created":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T18:13:11Z","timestamp":1555438391000},"page":"518-524","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":20,"title":["Emerging options in multiple myeloma: targeted, immune, and epigenetic therapies"],"prefix":"10.1182","volume":"2017","author":[{"given":"Shaji","family":"Kumar","sequence":"first","affiliation":[{"name":"Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"5","key":"2019111705152396900_B1","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"issue":"6","key":"2019111705152396900_B2","doi-asserted-by":"crossref","first-page":"422","DOI":"10.3322\/caac.21252","article-title":"Understanding biology to tackle the disease: Multiple myeloma from bench to bedside, and back","volume":"64","author":"Bianchi","year":"2014","journal-title":"CA Cancer J Clin"},{"key":"2019111705152396900_B3","doi-asserted-by":"crossref","DOI":"10.1182\/asheducation.V2012.1.342.3798324","article-title":"How to use new biology to guide therapy in multiple myeloma","volume-title":"Hematology Am Soc Hematol Educ Program","author":"Morgan","year":"2012"},{"issue":"2","key":"2019111705152396900_B4","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ccr.2007.07.003","article-title":"Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma","volume":"12","author":"Keats","year":"2007","journal-title":"Cancer Cell"},{"issue":"1","key":"2019111705152396900_B5","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.celrep.2017.03.025","article-title":"The mutational landscape of circulating tumor cells in multiple myeloma","volume":"19","author":"Mishima","year":"2017","journal-title":"Cell Reports"},{"key":"2019111705152396900_B6","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1038\/ncomms3997","article-title":"Heterogeneity of genomic evolution and mutational profiles in multiple myeloma","volume":"5","author":"Bolli","year":"2014","journal-title":"Nat Commun"},{"key":"2019111705152396900_B7","doi-asserted-by":"crossref","first-page":"6997","DOI":"10.1038\/ncomms7997","article-title":"APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma","volume":"6","author":"Walker","year":"2015","journal-title":"Nat Commun"},{"issue":"1","key":"2019111705152396900_B8","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.mayocp.2015.11.007","article-title":"Multiple myeloma: diagnosis and treatment","volume":"91","author":"Rajkumar","year":"2016","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"2019111705152396900_B9","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nm.3076","article-title":"Apoptosis therapy: driving cancers down the road to ruin","volume":"19","author":"Green","year":"2013","journal-title":"Nat Med"},{"issue":"14","key":"2019111705152396900_B10","doi-asserted-by":"crossref","first-page":"3901","DOI":"10.1182\/blood-2010-11-317438","article-title":"ABT-737 is highly effective against molecular subgroups of multiple myeloma","volume":"118","author":"Bodet","year":"2011","journal-title":"Blood"},{"issue":"1","key":"2019111705152396900_B11","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/leu.2013.216","article-title":"The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma","volume":"28","author":"Touzeau","year":"2014","journal-title":"Leukemia"},{"issue":"9","key":"2019111705152396900_B12","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1182\/blood-2011-11-390658","article-title":"Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics","volume":"119","author":"Kumar","year":"2012","journal-title":"Blood"},{"issue":"22","key":"2019111705152396900_B13","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.488.488","article-title":"Venetoclax monotherapy for relapsed\/refractory multiple myeloma: safety and efficacy results from a phase I study [abstract]","volume":"128","author":"Kumar","year":"2016","journal-title":"Blood"},{"issue":"22","key":"2019111705152396900_B14","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.975.975","article-title":"Venetoclax combined with bortezomib and dexamethasone for patients with relapsed\/refractory multiple myeloma [abstract]","volume":"128","author":"Moreau","year":"2016","journal-title":"Blood"},{"key":"2019111705152396900_B15","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.pharmthera.2016.03.020","article-title":"Importins and exportins as therapeutic targets in cancer","volume":"164","author":"Mahipal","year":"2016","journal-title":"Pharmacol Ther"},{"issue":"12","key":"2019111705152396900_B16","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1038\/leu.2013.172","article-title":"Genome-wide studies in multiple myeloma identify XPO1\/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276","volume":"27","author":"Schmidt","year":"2013","journal-title":"Leukemia"},{"issue":"22","key":"2019111705152396900_B17","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.491.491","article-title":"Selinexor and low dose dexamethasone (Sd) in patients with lenalidomide, pomalidomide, bortezomib, carfilzomib and anti-CD38 Ab refractory multiple myeloma (MM): STORM Study [abstract]","volume":"128","author":"Vogl","year":"2016","journal-title":"Blood"},{"issue":"22","key":"2019111705152396900_B18","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.977.977","article-title":"Selinexor in combination with bortezomib and dexamethasone (SdB) demonstrates significant activity in patients with refractory multiple myeloma (MM) including proteasome-inhibitor refractory patients: results of the phase I Stomp Trial [abstract]","volume":"128","author":"Bahlis","year":"2016","journal-title":"Blood"},{"issue":"22","key":"2019111705152396900_B19","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.973.973","article-title":"Final results of phase 1 MMRC trial of selinexor, carfilzomib, and dexamethasone in relapsed\/refractory multiple myeloma (RRMM) [abstract]","volume":"128","author":"Jakubowiak","year":"2016","journal-title":"Blood"},{"issue":"22","key":"2019111705152396900_B20","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1182\/blood-2015-12-686378","article-title":"Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 part 1","volume":"127","author":"Richardson","year":"2016","journal-title":"Blood"},{"issue":"2","key":"2019111705152396900_B21","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/bjh.14498","article-title":"Marizomib for central nervous system-multiple myeloma","volume":"177","author":"Badros","year":"2017","journal-title":"Br J Haematol"},{"issue":"14","key":"2019111705152396900_B22","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1182\/blood-2014-03-559963","article-title":"The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma","volume":"124","author":"Spencer","year":"2014","journal-title":"Blood"},{"issue":"suppl 1","key":"2019111705152396900_B23","first-page":"P273","article-title":"A phase IB study of the AKT inhibitor afuresertib in combination with bortezomib and dexamethasone in patients with relapsed\/refractory multiple myeloma: final results with long term follow-up","volume":"101","author":"Trudel","year":"2016","journal-title":"Haematologica"},{"issue":"21","key":"2019111705152396900_B24","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.301.301","article-title":"Phase 1 study update of the novel Pan-Pim kinase inhibitor LGH447 in patients with relapsed\/refractory multiple myeloma [abstract]","volume":"124","author":"Raab","year":"2014","journal-title":"Blood"},{"issue":"22","key":"2019111705152396900_B25","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.4526.4526","article-title":"Biomarker driven phase II clinical trial of trametinib in relapsed\/refractory multiple myeloma with sequential addition of the AKT inhibitor, GSK2141795 at time of disease progression to overcome treatment failure: a trial of the Princess Margaret Phase II Consortium [abstract]","volume":"128","author":"Trudel","year":"2016","journal-title":"Blood"},{"issue":"23","key":"2019111705152396900_B26","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.4263.4263","article-title":"Vemurafenib (VEM) in relapsed refractory multiple myeloma harboring BRAF(V600) mutations (V600m): a cohort of the histology-independent VE-Basket Study [abstract]","volume":"126","author":"Raje","year":"2015","journal-title":"Blood"},{"issue":"6","key":"2019111705152396900_B27","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1182\/blood-2015-10-646810","article-title":"Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma","volume":"127","author":"van de Donk","year":"2016","journal-title":"Blood"},{"issue":"17","key":"2019111705152396900_B28","doi-asserted-by":"crossref","first-page":"4574","DOI":"10.1158\/1078-0432.CCR-14-0695","article-title":"SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies","volume":"20","author":"Deckert","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2019111705152396900_B29","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/leu.2015.240","article-title":"SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide","volume":"30","author":"Jiang","year":"2016","journal-title":"Leukemia"},{"issue":"23","key":"2019111705152396900_B30","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.509.509","article-title":"A dose finding phase II trial of isatuximab (SAR650984, anti-CD38 mAb) as a single agent in relapsed\/refractory multiple myeloma [abstract]","volume":"126","author":"Martin","year":"2015","journal-title":"Blood"},{"issue":"suppl 1","key":"2019111705152396900_B31","first-page":"P274","article-title":"Updated data from a phase II dose finding trial of single agent isatuximab (SAR650984, anti-CD38 MAB) in relapsed\/refractory multiple myeloma (RRMM)","volume":"101","author":"Vij","year":"2016","journal-title":"Haematologica"},{"issue":"5","key":"2019111705152396900_B32","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/leu.2013.310","article-title":"Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma","volume":"28","author":"Atanackovic","year":"2014","journal-title":"Leukemia"},{"issue":"13","key":"2019111705152396900_B33","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1182\/blood-2010-02-271874","article-title":"The PD-1\/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody","volume":"116","author":"Benson","year":"2010","journal-title":"Blood"},{"issue":"10","key":"2019111705152396900_B34","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1038\/leu.2015.79","article-title":"PD-L1\/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma","volume":"29","author":"Paiva","year":"2015","journal-title":"Leukemia"},{"issue":"10","key":"2019111705152396900_B35","doi-asserted-by":"crossref","first-page":"e0139867","DOI":"10.1371\/journal.pone.0139867","article-title":"PDL1 expression on plasma and dendritic cells in myeloma bone marrow suggests benefit of targeted anti PD1-PDL1 therapy","volume":"10","author":"Sponaas","year":"2015","journal-title":"PLoS One"},{"issue":"23","key":"2019111705152396900_B36","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J Clin Oncol"},{"issue":"23","key":"2019111705152396900_B37","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.505.505","article-title":"Pembrolizumab in combination with lenalidomide and low-dose dexamethasone for relapsed\/refractory multiple myeloma (RRMM): Keynote-023 [abstract]","volume":"126","author":"San Miguel","year":"2015","journal-title":"Blood"},{"issue":"10","key":"2019111705152396900_B38","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1182\/blood-2017-03-775122","article-title":"Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed\/refractory multiple myeloma","volume":"130","author":"Badros","year":"2017","journal-title":"Blood"},{"issue":"11","key":"2019111705152396900_B39","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1056\/NEJMoa1504542","article-title":"Chimeric antigen receptor T cells against CD19 for multiple myeloma","volume":"373","author":"Garfall","year":"2015","journal-title":"N Engl J Med"},{"issue":"22","key":"2019111705152396900_B40","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.1147.1147","article-title":"B-cell maturation antigen (BCMA)-specific chimeric antigen receptor T cells (CART-BCMA) for multiple myeloma (MM): initial safety and efficacy from a phase I study","volume":"128","author":"Cohen","year":"2016","journal-title":"Blood"},{"key":"2019111705152396900_B41","first-page":"1","article-title":"First-in-human multicenter study of BB2121 anti-BCMA CAR T cell therapy for relapsed\/refractory multiple myeloma: updated results","volume":"102","author":"Lin","year":"2017","journal-title":"Haematologica"},{"issue":"10","key":"2019111705152396900_B42","first-page":"1139","article-title":"Idiotype vaccination of multiple myeloma patients using monocyte-derived dendritic cells","volume":"88","author":"Reichardt","year":"2003","journal-title":"Haematologica"},{"issue":"12","key":"2019111705152396900_B43","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1002\/ajh.21560","article-title":"Idiotype-pulsed antigen-presenting cells following autologous transplantation for multiple myeloma may be associated with prolonged survival","volume":"84","author":"Lacy","year":"2009","journal-title":"Am J Hematol"},{"issue":"8","key":"2019111705152396900_B44","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1097\/CJI.0000000000000097","article-title":"Lenalidomide synergistically enhances the effect of dendritic cell vaccination in a model of murine multiple myeloma","volume":"38","author":"Nguyen-Pham","year":"2015","journal-title":"J Immunother"},{"issue":"1","key":"2019111705152396900_B45","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/bjh.13245","article-title":"Phase I\/II study exploring ImMucin, a pan-major histocompatibility complex, anti-MUC1 signal peptide vaccine, in multiple myeloma patients","volume":"169","author":"Carmon","year":"2015","journal-title":"Br J Haematol"},{"key":"2019111705152396900_B46","doi-asserted-by":"crossref","first-page":"e207","DOI":"10.1038\/bcj.2014.29","article-title":"The role of epigenetics in the biology of multiple myeloma","volume":"4","author":"Dimopoulos","year":"2014","journal-title":"Blood Cancer J"},{"issue":"11","key":"2019111705152396900_B47","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S1470-2045(14)70440-1","article-title":"Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial","volume":"15","author":"San-Miguel","year":"2014","journal-title":"Lancet Oncol"},{"issue":"11","key":"2019111705152396900_B48","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S1470-2045(16)30375-8","article-title":"Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial","volume":"17","author":"Yee","year":"2016","journal-title":"Lancet Oncol"},{"issue":"11","key":"2019111705152396900_B49","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1158\/1078-0432.CCR-12-3752","article-title":"In vitro and in vivo antitumor activity of a novel alkylating agent, melphalan-flufenamide, against multiple myeloma cells","volume":"19","author":"Chauhan","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"13","key":"2019111705152396900_B50","doi-asserted-by":"crossref","first-page":"5216","DOI":"10.1158\/0008-5472.CAN-07-5725","article-title":"Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo","volume":"68","author":"Mitsiades","year":"2008","journal-title":"Cancer Res"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2017\/1\/518\/1250983\/hem00071.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2017\/1\/518\/1250983\/hem00071.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,23]],"date-time":"2019-11-23T14:48:40Z","timestamp":1574520520000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2017\/1\/518\/21183\/Emerging-options-in-multiple-myeloma-targeted"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,8]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12,8]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2017.1.518","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,8]]}}}